IPO Year:
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/26/2025 | $45.00 | Buy | Stifel |
| 3/7/2025 | $50.00 | Sector Outperform | Scotiabank |
| 2/20/2025 | $39.00 | Buy | Canaccord Genuity |
| 2/5/2025 | $44.00 | Buy | TD Cowen |
| 12/26/2024 | $38.00 | Buy | H.C. Wainwright |
| 12/18/2024 | Overweight | Cantor Fitzgerald |
4/A - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)
4/A - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)
4/A - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)
4/A - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)
4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Reporting)
4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Reporting)
4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Reporting)
4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Reporting)
3/A - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)
4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)
WAYNE, Pa., April 04, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025, at 2:00 p.m. PT. A live webcast of the fireside chat will be available on the Events and Presentations section of Palvella's website at www
WAYNE, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced a late-breaking oral presentation at the upcoming 15th World Congress of Pediatric Dermatology, taking place April 8-11, 2025, in Buenos Aires, Argentina. The oral presentation will highlight SELVA, a 24-week, Phase 3, single-arm, baseline-controlled clinical trial of QTORIN™ rapamycin 3.9% anhydrous gel for
Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic skin diseases Top-line results from SELVA, a Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs), on track for the first quarter of 2026 Top-line results from TOIVA, a Phase 2 single-arm, baseline-controlled trial evaluating QTORIN™ rapamycin for the treatment of
WAYNE, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its full year 2024 financial results on Monday, March 31, 2025. Palvella management will host a conference call for investors at 8:30 a.m. ET on Monday, March 31, 2025, to discuss financial results and provide a corporate update. To access the live webcast of the call with slides, please click here or visit the "Events & Presentations" sect
WAYNE, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that its management team will present at the TD Cowen 45th Annual Healthcare Conference on Tuesday March 4, 2025, at 2:30 p.m. ET. A live webcast of the presentation will be available on the Events and Presentations section of Palvella's website at www.palvellatx.com. An archived replay of the webcast will be available for approximately 90 days following the pre
Expansion reflects Palvella's commitment to serving all patients affected by microcystic lymphatic malformations (microcystic LMs) Company remains on track to report top line results from SELVA, a Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ rapamycin for the treatment of microcystic LMs, in Q1 2026 QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic LMs WAYNE, Pa., Feb. 10, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare gene
Publication reports 100% of participants were either "Much Improved" or "Very Much Improved" as rated by the Clinician Global Impression of Change following 12-weeks of QTORIN™ rapamycin FDA previously granted Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation to QTORIN™ rapamycin for microcystic lymphatic malformations (microcystic LMs) Ongoing Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ rapamycin for the treatment of microcystic LMs with topline data expected in Q1 2026 QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic LMs WAYNE, Pa., Jan. 10, 2025 (GLOBE NEWSWI
Phase 2 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of cutaneous venous malformations (cutaneous VMs) to enroll approximately 15 subjects at leading vascular anomaly centers across the U.S. Cutaneous VMs are a serious and lifelong genetic disease that can result in substantial morbidity and functional impairment of the skin affecting an estimated more than 75,000 diagnosed patients in the U.S. QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for cutaneous VMs WAYNE, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella)
Stifel initiated coverage of Palvella Therapeutics with a rating of Buy and set a new price target of $45.00
Scotiabank initiated coverage of Palvella Therapeutics with a rating of Sector Outperform and set a new price target of $50.00
Canaccord Genuity initiated coverage of Palvella Therapeutics with a rating of Buy and set a new price target of $39.00
TD Cowen initiated coverage of Palvella Therapeutics with a rating of Buy and set a new price target of $44.00
H.C. Wainwright initiated coverage of Palvella Therapeutics with a rating of Buy and set a new price target of $38.00
Cantor Fitzgerald initiated coverage of Palvella Therapeutics with a rating of Overweight
4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)
10-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)
8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)
8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)
S-8 - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)
424B3 - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)
EFFECT - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)
S-1/A - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)
8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)
S-1 - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)
SCHEDULE 13G - PALVELLA THERAPEUTICS, INC. (0001583648) (Subject)
Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic skin diseases Top-line results from SELVA, a Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs), on track for the first quarter of 2026 Top-line results from TOIVA, a Phase 2 single-arm, baseline-controlled trial evaluating QTORIN™ rapamycin for the treatment of
WAYNE, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its full year 2024 financial results on Monday, March 31, 2025. Palvella management will host a conference call for investors at 8:30 a.m. ET on Monday, March 31, 2025, to discuss financial results and provide a corporate update. To access the live webcast of the call with slides, please click here or visit the "Events & Presentations" sect